Renal Denervation Technologies Market

Renal Denervation Technologies Market Growth Outlook (2022-2026)

The global renal denervation technologies market is anticipated to increase at a prolific CAGR of 40% over the 2022-2026 forecast period. The market is expected to secure a market value of around US$ 720 million by 2026, up from US$ 186 million in 2022.

Demand for radiofrequency-based technology is expected to increase at 35% CAGR over the coming years. It is anticipated that the excellent efficacy of radiofrequency-based technology, which has been demonstrated in various trials, would boost the significance of these devices across geographies.

Report Attributes	Details
Market Size (2022)	US$ 186 Million
Projected Market Value (2026)	US$ 720 Million
Global Market Growth Rate (2022-2026)	40% CAGR
Market Share of Radiofrequency-based Technology	75%
Key Companies Profiled	Medtronic Boston Scientific Corp. Symple Surgical, Inc. Terumo Corporation Ablative Solutions, Inc. Abbott Laboratories Renal Dynamics Limited Mercator MedSystems, Inc. ReCor Medical, Inc.

Revenue Analysis of Renal Denervation Technologies (2017-2021) Vs. Market Outlook (2022-2026)

“Rising Demand for Minimally-Invasive Procedures for Hypertension Treatment”

According to Fact.MR, a market research and competitive intelligence provider, demand for renal denervation technologies is expected to increase at a stupendous CAGR of 40% from 2022 to 2026.

Renal denervation is a microsurgical solution for hypertension. Radiofrequency ablation burns the neurons in the renal arteries. Blood pressure is reduced, and nerve stimulation is decreased. This approach is typically used to get better results when drug treatment hasn't worked to relieve symptoms.

With the help of ultrasound or radiofrequency pulses, the nerves that line the renal artery wall are destroyed. A decrease in sympathetic kidney activity lowers blood pressure.

The renal denervation devices market is driven by the rising prevalence of chronic disorders including obesity in both, children and adults.

• More than 39 million children under the age of five were overweight in 2020, according to statistics from WHO.

Given that high leptin levels in obese individuals might cause hypertension by stimulating the formation of blood vessels in the hypothalamus, this disease is anticipated to increase the demand for renal nerve denervation therapy.

Moreover, market growth of renal denervation is attributed to the increase in demand for minimally-invasive procedures for hypertension treatments.

What’s Shaping Renal Denervation Technologies Market Growth?

“Increase in Funding for R&D Initiatives for Treatment of Renal Disorders”

Demand for renal denervation procedures is anticipated to be aided by various authorities and government organizations increasing funding for R&D initiatives for renovascular hypertension treatment. Additionally, advancements in renal denervation devices could propel the industry.

One of the key factors increasing the adoption of the renal denervation method is the number of new skills it introduces. The drawbacks of high frequency-based renal denervation systems can be overcome by an ultrasonic RDN device. Without making direct touch with the tissue, high-frequency sound waves and ultrasonic energy assist in the removal of nerves.

This lessens the risk of renal artery injury. This quality makes this method preferred by a sizable number of patients worldwide. The effectiveness of these strategies will also be greatly enhanced by incorporating technology into these kinds of health practices and paving the opportunities in the renal denervation industry.

What Obstacles Do Renal Denervation Device Manufacturers Face?

“Lack of Skilled Professionals & High Pricing of Renal Denervation Devices”

Inadequate clinical data is one issue troubling the global market for renal denervation technologies, which makes it difficult to obtain regulatory body approval for new products. Currently, this is considerably impeding the renal denervation therapy market expansion.

The restricted use of renal denervation techniques is caused by a lack of skilled professionals. Reduced demand for renal artery denervation devices is being caused by this, along with decreasing diagnostic rates among the general population.

The risk of infection following surgery is one of the main concerns limiting the demand for renal denervation systems. Any procedure involving cuts, incisions, or other penetrations into the skin has the potential to infect the patient.

Most surgical wound infections become apparent one month following the procedure. Numerous issues with the wound or the patient's body may arise as a result of the post-surgical infection. The market may have growth barriers due to these methods' high costs.

How are Start-ups Adding to Renal Denervation Technologies Market Progress?

“New Market Entrants Focusing on Advancements in Renal Denervation Technologies”

New companies are continuously attempting to create reliable systems for easing the difficulties associated with high blood pressure and hypertension. More and more clinical trials are being conducted to improve renal denervation technologies.

• A start-up based in Israel – SoniVie - received FDA approval for its novel treatment for hypertension. Patients with hypertension can benefit from renal artery denervation using the cutting-edge ultrasound technology TIVUS. The main treatment made available by TIVUS, renal denervation, is a minimally-invasive surgery that safely removes or ablates renal artery nerves using high-frequency, non-focused ultrasound energy. This procedure lowers blood pressure by reducing nerve activity.

Why is Europe Expected to Lead the Global Renal Denervation Technologies Market?

“Rapid Increase in Drug-resistant Hypertension Cases in Europe”

The renal denervation technologies market is dominated by Europe, and it is anticipated that this trend will continue over the forecast period.

• Over 40% of Europeans over the age of 25 have hypertension, and 10% of those have medication-resistant hypertension, according to a research study.

Numerous renal denervation devices with CE authorization are available in Europe. Growing R&D efforts to create effective technologies for renal artery stenosis treatments are the main driver fueling the market expansion.

The introduction of new products in the area will also aid in the expansion of the market. The increase in drug-resistant hypertension cases could drive market expansion in the region.

Country-wise Insights

What Driving Demand for Renal Denervation Technologies in the U.S.?

“Increase in Product Authorization Requests in the U.S.”

Increased incidences of uncontrolled hypertension, a changing lifestyle among the populace, and an increase in product authorization requests are anticipated to fuel market expansion in the U.S.

The rapid growth of uncontrolled hypertension caused by rapid urbanization, technological advancements in the production of efficient devices, and an increase in FDA approvals are three major factors contributing to the market growth in the United States over the forecast period.

Why is the Market for Renal Denervation Technologies So Prominent in China?

“High Patient Awareness Regarding Renal Denervation Systems in China”

The renal denervation technologies market in China is projected to increase at a CAGR of 45% from 2022 to 2026.

The market in China is anticipated to experience the fastest growth rate over the projected period due to the rising use of cutting-edge tools and methods for the treatment of resistant hypertension.

Many unmet medical requirements for the treatment of hypertension, a rise in the knowledge of the usage of advanced technology such as renal denervation systems, and a high prevalence of resistant hypertension are driving the market growth in China.

The prevalence of a sizable target population and rising rates of diabetes, obesity, and other lifestyle disorders are the factors driving the market revenue.

Category-wise Insights

Which Renal Denervation Product Has Gained Immense Traction?

“Symplicity Segment Gaining Traction Due to Rising Usage in Treating Excessive Blood Pressure”

Based on product, the renal denervation technologies market is classified into symplicity, vessix, enlightn, paradise, and iberis.

The symplicity segment is expected to hold the largest revenue share of the renal denervation technologies market. Because it provides low-level radiofrequency energy, which lowers the possibility that high-level radiofrequency would cause radiation harm to body tissues, this device is most frequently used to treat hypertension.

Additionally, it provides a low-risk way to treat excessive blood pressure. The expansion of this market is anticipated to blossom over the decade because it results in reduced blood loss.

Which Technology Holds a Dominant Stance in the Market?

“Rising Penetration of Radiofrequency-based Technology for Resistant Hypertension Treatment”

Based on technology, the renal denervation technologies market is segmented into radiofrequency-based, ultrasound-based, and micro-infusion-based.

Radiofrequency-based technology accounts for 75% share of the global market because it is effective, secure, and quick, radiofrequency is the most widely utilized renal denervation method.

Resistant hypertension can be effectively controlled by radiofrequency renal denervation, and a single surgery can drop blood pressure levels for up to two years. According to a study, in patients with severe nerve blocks, radiofrequency-based technology is 70-80% successful.

Also, radiofrequency-based ablation procedures can be repeated after two or three weeks if a patient only experiences a modest amount of alleviation.

Which End User is Expected to Generate High Revenue for Market Players?

“Rise in Funding by Government Organizations for Developing Multi-specialty Hospitals”

The renal denervation technologies market is divided into hospitals, specialty clinics, research and academic institutions, and ambulatory care centers based on the end user.

Demand for renal denervation technologies in hospitals is expected to rise at the highest CAGR over the forecast period. The industry is expanding due to the increased funding by government organizations for developing multi-specialty hospitals to address the rise of deadly diseases. Additionally, professional practitioners, nurses, surgeons, and other related health professionals make up the majority of the hospital workforce.

Competitive Landscape

Renal denervation device manufacturers are requesting authorization to employ renal denervation systems and devices in clinical trials. A significant driver of the renal denervation industry is the rise in clinical trials for the treatment of diseases, including hypertension and blood pressure.

This increase in trials is anticipated to increase the demand for renal denervation and present new prospects for renal denervation companies.

For instance :

• In 2022, Microsoft, an American global technology business, partnered with Johnson & Johnson. As part of this partnership, Johnson & Johnson is set to use Microsoft's cloud computing capabilities to connect patients and surgeons in an ecosystem for digital surgery.

Key Segments of Renal Denervation Technologies Industry Research

• By Product :

  • Symplicity
  • Vessix
  • EnligHTN
  • Paradise
  • Iberis
  • Others

• By Technology :

  • Radiofrequency-based
  • Ultrasound-based
  • Micro-infusion-based

• By End User :

  • Hospitals
  • Specialty Clinics
  • Research & Academic Institutes
  • Ambulatory Care Centers

• By Region :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa